Back to Investors
Old College Capital

Old College Capital

Accelerator

Old College Capital is the in-house venture investment fund of the University of Edinburgh supporting high-growth, early-stage university-associated businesses.

Portfolio

8

companies


Portfolio companies

I

IONATE

IONATE develops intelligent transformer technology to modernise electricity distribution grids.

NA

Net AI

Net AI uses artificial intelligence and cloud computing to provide real-time demand insights for 5G network providers.

WG

Wobble Genomics

Wobble Genomics provides advanced hardware and software tools for genetic sequencing.

A

Aveni

Aveni develops artificial intelligence platforms for speech analytics in business.

MN

Manus Neurodynamica

Manus Neurodynamica develops digital health tools to detect early signs of neurological conditions.

Sofant Technologies

Sofant Technologies

Sofant Technologies builds energy efficient antenna technology platforms for 5G and satellite communications.

MiAlgae

MiAlgae

MiAlgae produces sustainable microalgae from whisky by-products for the aquaculture and pet food sectors.

I

Invizius

Invizius develops anti-inflammatory technology to reduce mortality rates among dialysis patients.


Team

AY

Andrea Young

Head of Investment


Recent investments

Seed
£3.3M

The seed round was led by IQ Capital with participation from several specialist energy and deep-tech investors.

"Working through a pandemic, scaling what was just an idea to fully functioning devices in less than three years, shows not only our team’s skill and dedication but the conviction of our network that IONATE is a key technology for the energy transition. With visionary experts from deep-tech venture capital, the utility sector, and academia in this round, we could not have chosen more strategic partners for achieving IONATE’s huge potential. I’m very excited for the next chapter and to work side-by-side with our investors and partners on what promises to be a time of extraordinary development and growth."
— Matthew Williams, CEO
Seed
£1.1M

The TRICAPITAL-led round will fund team expansion and sector diversification for the Edinburgh fintech.

"In the new world, AI can be adopted throughout the customer journey, driving new insight, significant efficiency gains and better protecting the vulnerable. It’s a win-win situation. By using AI to help automate processes like quality assurance and risk monitoring, material cost reductions can be achieved. At the same time, companies gain targeted insights on customer experience and training opportunities for customer-facing staff."
— Joseph Twigg, CEO
Seed
£2.3M

EMV Capital led the pre-series A round to support product development and partnership activities in 5G and satellite communications.

"We are very pleased to have supportive investors who understand the value of semiconductor-based hardware. This funding will be used to complete the development of our core RF technology platform. It will also support our activities with an ecosystem of corporate partners who share Sofant’s belief that RF MEMS will disrupt the market for high frequency SatCom and 5G antenna applications. It is a very exciting time for Sofant, and we look forward to working with our partners to change the way high frequency antenna systems are designed and built."
— David Wither, CEO
Seed
£1.0M

The financing round was supported by Equity Gap, Scottish Investment Bank, Old College Capital and Hillhouse Group.

"MiAlgae has essentially taken a by-product from one industry and turned it into a solution for another industry. Through the application of biotechnology, MiAlgae is finding solutions to feed the world’s population, and with the global aquaculture industry set to double in size in the next ten years, this is a very promising business indeed."
— Andrew Vernon, Representative
Series A
£2.8M

The funding round was led by Mercia to support pre-clinical testing and manufacturing as the company prepares for clinical trials.

"Our goal is to bring much-needed improvement to the lives of three million dialysis patients. This investment allows us to take a big step towards this, and we are delighted to have won the backing of a consortium of smart, well-funded investors."
— Richard Boyd, CEO